Sex Disparity in Characteristics, Management, and In-Hospital Outcomes of Patients with ST-Segment Elevated Myocardial Infarction: Insights from Henan STEMI Registry

Table 2

Treatment delay and use of guideline-recommended acute drugs between the study groups.

Variable	Men (N = 3829)	Women (N = 1234)	value
Treatment delay
Onset to FMC (minute)	190 (101, 540)	255 (120, 734)	<0.001
Onset to fibrinolysis (minute)	185 (125, 275)	218 (150, 339)	<0.001
FMC to fibrinolysis (minute)	45 (28, 78)	50 (31, 89)	0.047
Onset to PCI (minute)^ϕ	243 (155, 390)	307 (188, 450)	<0.001
FMC to PCI (minute)^ϕ	65 (42, 95)	62 (41, 95)	0.469
Guideline-recommended acute drugs
Aspirin	3091 (80.7)	926 (75.0)	<0.001
P2Y12 antagonist	3214 (83.9)	965 (78.2)	<0.001
DAPT	3048 (79.6)	905 (73.3)	<0.001
Statin	639 (16.7)	246 (19.9)	0.009
Beta-blocker (24 h)	997 (26.0)	316 (25.6)	0.764

Data are expressed as n (%) and median (IQR) unless otherwise noted. Onset to fibrinolysis and FMC to fibrinolysis were available among patients who were given fibrinolytic therapy. ^ϕOnset to PCI and FMC to PCI were available among patients who were received primary PCI. STEMI, ST-elevation myocardial infraction; FMC, first medical contact; PCI, percutaneous coronary intervention; P2Y12 antagonist, clopidogrel and ticagrelor; DAPT: dual-antiplatelet therapy; loading dose medicine: medicine used within 24 hours after being admitted.